{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-002092","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2025-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.919257+00:00","generated_at":"2026-05-27T20:50:36.267212+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Abbott Q4 organic base business sales +10.1%; FY2025 adj. EPS guidance $5.05-$5.25","bullets":["Q4 reported sales $11.0B (+7.2% YoY); organic base business (ex-COVID) grew 10.1%.","Q4 GAAP diluted EPS $5.27; adjusted diluted EPS $1.34 (core measure).","Full-year 2024 sales $42.0B (+4.6% reported); organic base business +9.6%; adjusted EPS $4.67.","Medical Devices Q4 sales $5.05B (+13.7% reported); Diabetes Care FreeStyle Libre grew 22.7% to $1.86B.","FY2025 guidance: organic sales growth 7.5%-8.5%; adjusted EPS $5.05-$5.25; op. margin 23.5%-24.0%."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-002092","json":"https://secwatch.observer/filing/0001628280-25-002092.json","markdown":"https://secwatch.observer/filing/0001628280-25-002092.md","text":"https://secwatch.observer/filing/0001628280-25-002092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000162828025002092/0001628280-25-002092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000162828025002092/abt-20250122.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T20:50:36.267212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}